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Does Dobutamine Stress Perfusion Imaging Solve
the Riddle of Ischemia in LBBB?*
Eike Nagel, MD, PHD,y William A. Zoghbi, MDz
London, United Kingdom; and Houston, TexasIn patients with an intermediate likelihood for
the presence of coronary artery disease (CAD), most
of today’s guidelines require proof of myocardial
ischemia before invasive angiography. Similarly,
signiﬁcant myocardial ischemia should be demon-
strated before revascularization. The most recent
European Society of Cardiology guidelines for pa-
tients with stable coronary artery disease leave the
choice of the test to the practitioner on the basis of
local expertise (1). The recently published multi-
modality appropriateness criteria for detection and
risk assessment in stable ischemic heart disease have
rated various imaging modalities on the basis of
existing evidence, assuming they are equally available
with appropriate quality and expertise, while sug-
gesting to keep cost-effectiveness and value in mind
when ordering such tests (2).See page 490Direct comparisons between different imaging
modalities are rare, as patients have to undergo both
imaging modalities as well as an invasive reference
standard to allow for a direct and unbiased com-
parison. Most studies so far have been comparing
adenosine stress perfusion with cardiac magnetic
resonance (CMR) and single-photon emission
computed tomography as the latter is the most
frequently performed test in patients with stable
CAD but is burdened by radiation and low spatial*Editorials published in JACC: Cardiovascular Imaging reﬂect the views
of the authors and do not necessarily represent the views of JACC:
Cardiovascular Imaging or the American College of Cardiology.
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or superiority of CMR to single-photon emission
computed tomography (3,4).
Less data is available for the comparison of dobut-
amine stress cardiac magnetic resonance (DSCMR)
and dobutamine stress echocardiography (DSE)
even though DSE is among the most frequently
used tests in stable chest pain patients, especially in
Europe. In an early study in 1999, Nagel et al. (5)
demonstrated a superior diagnostic accuracy for
DSCMR versus DSE to detect signiﬁcant CAD;
however, the methods used no longer reﬂect today’s
state-of-the art echocardiography or CMR tech-
nology. In addition, there are no data on speciﬁc
subgroups such as patients with left bundle branch
block (LBBB), which pose speciﬁc challenges on
noninvasive imaging due to their asynchronous myo-
cardial motion and thickening.
In this issue of iJACC, Mordi et al. (6) provide
a comparison of contrast-enhanced DSE with
DSCMR and invasive angiography in 82 patients
with LBBB. In addition to high-dose dobutamine
wall motion imaging, they assessed ﬁrst-pass
perfusion during an intermediate dose of do-
butamine (20 mg dobutamine/kg body weight/min)
and the presence of scar tissue by late gadolinium
enhancement (LGE) CMR. They found similar
sensitivity (70.6%) and a tendency toward higher
speciﬁcity of DSCMR wall motion imaging in
comparison to DSE (87.5% vs. 72.9%), with a
resultant tendency for better accuracy (80.4% vs.
72.0%). This is further improved by adding perfusion
imaging at 20 mg dobutamine/kg body weight and
LGE. Thus, in patients with LBBB, a “com-
prehensive CMR” examination that includes do-
butamine stress wall motion, ﬁrst-pass perfusion
imaging at an intermediate dobutamine dose, and
LGE appears to be an excellent test to detect sig-
niﬁcant CAD and seems to overcome some of
Figure 1. Coronary Vasodilation and Rate-Pressure Product as
a Response to Dobutamine
Reprinted, with permission, from Bartunek et al. (9). Pa ¼ aortic pressure;
Pd ¼ distal coronary pressure.
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500the limitations that methods which rely only on
wall motion (DSCMR and particularly DSE)
have in this population.
The paper by Mordi et al. (6) provides important
answers and closes a knowledge gap on which im-
aging modality to use in this important and difﬁcult
subgroup of patients. However, further important
questions are also raised.
What Is the Best Dose for
Dobutamine Stress Perfusion Imaging?
It is interesting that perfusion imaging improved
speciﬁcity but reduced sensitivity in comparison to
wall motion imaging. On the basis of the ischemic
cascade, one would expect a higher sensitivity of
perfusion imaging as perfusion defect occurs earlier
than wall motion abnormalities do. In addition,
inducible wall motion abnormalities usually occur
in areas with transmural or signiﬁcant endocardial
perfusion defects. Previous studies adding perfusion
imaging to wall motion assessment have also rather
demonstrated an increased sensitivity, both for CMR(7) as well as for echocardiography (8). In some
studies, a lower speciﬁcity was observed when adding
perfusion analysis to the diagnostic workup (7).
A possible explanation for this observation is the
use of 20 mg dobutamine/kg body weight/min in the
current study, whereas most studies so far have pro-
posed perfusion imaging at peak dose to achieve
maximal vasodilation. In an invasive study, Bartunek
et al. (9) have assessed coronary pressure during
various doses of dobutamine. They found signiﬁcant
vasodilation at 20 mg dobutamine with some (but not
statistically signiﬁcant) additional dilation at 30 mg
dobutamine (Fig. 1). Additional infusion of adeno-
sine did not lead to further vasodilation. From the
original data, one may argue that a dose of 30 mg
may slightly improve sensitivity due to the increased
vasodilation. At the same time, higher heart rates
can decrease image quality of CMR perfusion im-
aging, potentially leading to a lower speciﬁcity.
Although the answer to this question cannot be
found in the current data, the dose proposed by
Mordi et al. (6) appears to add value to the stress
examination and was safe and feasible. Lastly, the
effect on sensitivity and speciﬁcity of any stress test
is also inﬂuenced by the criteria used to denote
CAD. The comprehensive CMR examination in
the current study (6) yielded optimal results when
using a perfusion defect in a region of induced wall
motion abnormality (as opposed to either ﬁnding) to
increase speciﬁcity or scar by LGE with or without
additional ischemia to increase sensitivity in patients
with LBBB. However, the observed LGE pattern
in the studied group was typical of CAD in all
patients. Further experience is needed to validate
these observations in the larger clinical setting,
particularly in patients with a mixed scar pattern.
Should Perfusion Always Be Added
to Wall Motion Assessment?
Whereas early studies did not demonstrate supe-
rior or additional value of perfusion imaging to
wall motion assessment (10), this has changed in
recent years. Most likely this is due to the improved
methodology used for perfusion imaging resulting in
high quality datasets with high spatial resolution.
Falcão et al. (8) nicely demonstrated the added value
of perfusion imaging to both modalities, echocar-
diography as well as CMR, for improved sensitivity.
The value of reversible perfusion abnormalities (and
LGE) will likely be even more important in patients
with LBBB and depressed left ventricular function.
In the study by Mordi et al. (6), the population
had intermediate risk for coronary disease, and we
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501suspect ventricular function was preserved overall
(but no assessment was provided). The difﬁculties of
assessing CAD in the presence of LBBB are com-
pounded in patients with depressed ventricular func-
tion, where cardiomyopathy and/or coexistent CAD
maybe important.More studies are needed to evaluate
the relative value of each component of wall motion,
perfusion, and LGE in ischemia detection and their
impact in a less select population with LBBB.
What Is the Correct Reference Standard?
Obviously any study in patients with CAD today is
challenged by the lack of an optimal reference stan-
dard. While we understand that fractional ﬂow
reserve downgrades many stenoses deemed hemo-
dynamically signiﬁcant by invasive angiography, the
correlation of FFR with ischemic burden or the
ischemic burden relevant to patients’ symptoms and
prognosis are largely unknown. By using a 70% cutoff
value for signiﬁcance of a stenosis, the investigators
avoided having toomany “false negative” noninvasive
tests in patients with stenosis but no or only smallareas of ischemia. However, the accuracy of the
CMR study was measured against an anatomical test
and as such may not reﬂect a truly better perfor-
mance. In a recent publication, Shaw et al. have
summarized criteria for different imaging modalities
to assess ischemic burden and provided some ﬁrst
estimate on the predictive value of different sever-
ities of myocardial ischemia. Studies such as the
ISCHEMIA (International Study of Comparative
Health Effectiveness With Medical and Invasive
Approaches) trial or the MR-INFORM (MR
Perfusion Imaging to Guide Management of Pa-
tients With Stable Coronary Artery Disease) study
(11) will provide a better understanding on the impact
of ischemia on outcome. Once such data is available,
we will also be able to better deﬁne a reference stan-
dard against which to measure “superiority.”
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